CN117177990A - 用于制备的工程dna酶1样2和在治疗中的用途 - Google Patents

用于制备的工程dna酶1样2和在治疗中的用途 Download PDF

Info

Publication number
CN117177990A
CN117177990A CN202280029044.XA CN202280029044A CN117177990A CN 117177990 A CN117177990 A CN 117177990A CN 202280029044 A CN202280029044 A CN 202280029044A CN 117177990 A CN117177990 A CN 117177990A
Authority
CN
China
Prior art keywords
enzyme
subject
seq
pharmaceutical composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280029044.XA
Other languages
English (en)
Chinese (zh)
Inventor
托碧昂斯·A·富驰
安盖莱娜·皮拉桑纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neutrex Co ltd
Original Assignee
Neutrex Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutrex Co ltd filed Critical Neutrex Co ltd
Publication of CN117177990A publication Critical patent/CN117177990A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202280029044.XA 2021-02-17 2022-02-17 用于制备的工程dna酶1样2和在治疗中的用途 Pending CN117177990A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150433P 2021-02-17 2021-02-17
US63/150,433 2021-02-17
PCT/US2022/016771 WO2022178110A2 (en) 2021-02-17 2022-02-17 Dnase 1-like 2 engineered for manufacturing and use in therapy

Publications (1)

Publication Number Publication Date
CN117177990A true CN117177990A (zh) 2023-12-05

Family

ID=82932330

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280029044.XA Pending CN117177990A (zh) 2021-02-17 2022-02-17 用于制备的工程dna酶1样2和在治疗中的用途

Country Status (6)

Country Link
US (1) US20240228995A9 (enExample)
EP (1) EP4294824A4 (enExample)
JP (1) JP2024508753A (enExample)
KR (1) KR20240004247A (enExample)
CN (1) CN117177990A (enExample)
WO (1) WO2022178110A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112996911A (zh) * 2018-10-08 2021-06-18 纽特雷斯股份有限公司 用于制造和疗法的脱氧核糖核酸酶的工程改造

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection
CN111566207A (zh) * 2017-08-18 2020-08-21 纽特雷斯股份有限公司 工程化的dna酶酶及其在疗法中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
AU2018393110B2 (en) * 2017-12-20 2023-04-27 Poseida Therapeutics, Inc. VCAR compositions and methods for use
CN112996911A (zh) * 2018-10-08 2021-06-18 纽特雷斯股份有限公司 用于制造和疗法的脱氧核糖核酸酶的工程改造

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111566207A (zh) * 2017-08-18 2020-08-21 纽特雷斯股份有限公司 工程化的dna酶酶及其在疗法中的用途
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAISUKE SHIOKAWA等: "Characterization of the human DNAS1L2 gene and the molecular mechanism for its transcriptional activation induced by inflammatory cytokines", GENOMICS, vol. 84, 15 April 2004 (2004-04-15), pages 95 - 105 *
L. ECKHART等: "DNase1L2 suppresses biofilm formation by Pseudomonas aeruginosa and Staphylococcus aureus", BRITISH JOURNAL OF DERMATOLOGY, vol. 156, no. 6, 25 April 2007 (2007-04-25), pages 1342 - 1345 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112996911A (zh) * 2018-10-08 2021-06-18 纽特雷斯股份有限公司 用于制造和疗法的脱氧核糖核酸酶的工程改造

Also Published As

Publication number Publication date
KR20240004247A (ko) 2024-01-11
JP2024508753A (ja) 2024-02-28
WO2022178110A3 (en) 2022-10-27
US20240132863A1 (en) 2024-04-25
EP4294824A4 (en) 2025-01-01
EP4294824A2 (en) 2023-12-27
US20240228995A9 (en) 2024-07-11
WO2022178110A2 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
JP3468778B2 (ja) ヒトｄｎアーゼｉ過反応性変異体
US7968512B2 (en) Conjugates that contain the homeodomain of antennapedia
EP3581207B1 (en) Fusion proteins comprising hoxd12 and nemo binding domain and their use
JP2023504341A (ja) ヒトコラーゲンｘｖｉｉ型ポリペプチド、その製造方法および使用
CZ284204B6 (cs) Zvyšování sekrece polypeptidů
KR20230017804A (ko) Rhfgf21 융합 단백질, rhfgf21 융합 단백질을 인코딩하는 폴리뉴클레오티드, rhfgf21 융합 단백질을 포함하는 조성물, 및 rhfgf21 융합 단백질의 용도
CN107011430B (zh) 一种具有生物学活性的截短的生长分化因子11及其制备方法
US20240228995A9 (en) Dnase 1-like 2 engineered for manufacturing and use in therapy
JP2000505285A (ja) ヒトｄｎアーゼ
JP5185914B2 (ja) ヒトｄｎアーゼｉｉ
US9765323B2 (en) Thermally stable enzymes, compositions thereof and method of using same
JPH07503367A (ja) ヒト　アポリポタンパク質ａｉｖから透導されたポリペプチド，その製造及びその利用
Kimura et al. The primary structures of ribosomal proteins S14 and S16 from the archaebacterium Halobacterium marismortui. Comparison with eubacterial and eukaryotic ribosomal proteins.
JPH02150282A (ja) 修飾ヒトｐｓｔｉ
Bobek et al. Efficient production of biologically active human salivary cystatins in Escherichia coli
CN116143903B (zh) 肽聚糖识别蛋白-3及其制备方法和应用
US12150976B2 (en) Treatment of immune dysregulation disorders
JP4643932B2 (ja) アメロゲニン融合タンパク質
WO2000012723A1 (en) A novel human lysozyme gene, its encoding polypeptide and the method for preparing them
NZ523274A (en) Co-expression of recombinant proteins via an expression vector comprising a nucleic acid encoding a non-proteolytic analogue of a Hin47 protein of a strain of Haemophilus
JPH0675509B2 (ja) ヒト・膵臓エラスタ−ゼ▲ｉｉｉ▼ｂ
JPH07196688A (ja) 新規な生理活性ポリペプチド、その製造方法及び用途
JPH0940583A (ja) 組換えＤｅｒ ｆ ＩＩＩアレルゲン及びその製造法
JPH0625289A (ja) 新規ポリペプチド、新規ｄｎａ、医薬組成物およびポリペプチドの製造方法
JPH06253838A (ja) ヒト・膵臓エラスターゼｉｉｉｂ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination